ReviewEuropean urology2022

International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.

Mathieu Roumiguié et al.PubMed ↗Publisher ↗

No numbers read from the abstract.